www.fdanews.com/articles/174113-fda-awards-destiny-pharma-qidp-designation-for-staph-drug
FDA Awards Destiny Pharma QIDP Designation for Staph Drug
November 17, 2015
Antimicrobial drugmaker Destiny Pharma has won qualified infectious disease product designation for its lead candidate XF-73 to prevent postsurgical staph infections, including multiple drug-resistant MRSA.
Phase 1/2a studies conducted in Europe show the compound reduces the number of bacteria in the nose quickly. XF-73 (exeporfinium chloride) is being studied in a clinical trial sponsored by NIH’s National Institute of Allergy and Infectious Diseases that is expected to be completed shortly.